<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Of 1774 patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> given <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> (MTZ) with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (n = 492) or with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="27504">mitomycin C</z:chebi> (n = 1282), nine developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after a median of 2.5 years </plain></SENT>
<SENT sid="1" pm="."><plain>Median duration of survival from diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 10 months and six patients died </plain></SENT>
<SENT sid="2" pm="."><plain>The crude incidence of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after MMM or MM chemotherapy was 15 per 100,000 patient years follow-up, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively </plain></SENT>
<SENT sid="3" pm="."><plain>MTZ-based regimens carry a 10 x higher risk of subsequent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> compared to that seen in the general population </plain></SENT>
</text></document>